Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MANNKIND CORPMNKD · Entity 4792 | Director · Chief Executive Officer | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,796,979 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Exercise / conversion · Acquired 350,260 · Balance 2,796,979 F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. F2: Includes 4,409 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,604,160 |
Reported balance
After 2026-07-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-15 · Tax withholding · Disposed 192,819 · Balance 2,604,160 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,556,679 |
Reported balance
After 2026-07-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-15 · Tax withholding · Disposed 47,481 · Balance 2,556,679 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,492,683 |
Reported balance
After 2026-07-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-07-15 · Tax withholding · Disposed 63,996 · Balance 2,492,683 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,433,779 |
Reported balance
After 2026-07-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-07-15 · Tax withholding · Disposed 58,904 · Balance 2,433,779 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Exercise / conversion · Disposed 350,260 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria.
F2: Includes 4,409 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 569,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062071 · ownership.xml · derivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 569,000 Underlying: Common Stock, $.01 Par Value · 569,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F5 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F5 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 465,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062071 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,614,260 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 10, 2024 Filed May 15, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 34,830 | $4.32 | $150,465.60 |
DisclosureSEC source: 0000950170-24-059961 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,149,260 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 30,581 | $3.27 | $99,999.87 |
DisclosureSEC source: 0001209191-24-002738 · doc4.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,184,090 F3 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| December 31, 2023 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 209 | $3.09 | $645.81 |
DisclosureSEC source: 0001209191-24-002738 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,153,509 F2 · kind: Includes 209 shares of common stock purchased under the Company's Employee Stock Purchase Plan on December 31, 2023 in an exempt transaction. Read SEC document |
| December 15, 2023 Filed Dec 16, 2023 02:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 90,482 | $4.00 | $361,928.00 |
DisclosureSEC source: 0001209191-23-058899 · doc4.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,148,665 F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established September 1, 2023. All transactions contemplated by such plan have now been completed. Read SEC document |
| December 14, 2023 Filed Dec 16, 2023 02:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 100,000 | $4.00 | $400,000.00 |
DisclosureSEC source: 0001209191-23-058899 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239,147 F2 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established September 1, 2023. Read SEC document |
| December 14, 2023 Filed Dec 16, 2023 02:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.00 | $40,000.00 |
DisclosureSEC source: 0001209191-23-058899 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,339,147 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. All transactions contemplated by such plan have now been completed. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.25 | $42,500.00 |
DisclosureSEC source: 0001209191-23-054255 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,349,147 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.61 | $46,100.00 |
DisclosureSEC source: 0001209191-23-051262 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,359,147 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.08 | $40,800.00 |
DisclosureSEC source: 0001209191-23-051766 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,359,147 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. F2 · price: Correction of price. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | OtherCommon Stock, $.01 Par Value | 66,892 | $4.91 | $328,439.72 |
DisclosureSEC source: 0001209191-23-048259 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,369,147 F2 · kind: Reporting person transferred 66,892 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree on September 5, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.61 | $46,100.00 |
DisclosureSEC source: 0001209191-23-048259 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,436,039 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| August 27, 2023 Filed Aug 29, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 50,696 | $4.72 | $239,285.12 |
DisclosureSEC source: 0001209191-23-047553 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,446,039 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.57 | $45,686.00 |
DisclosureSEC source: 0001209191-23-044093 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,496,735 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| July 05, 2023 Filed Jul 8, 2023 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 5,586 | $4.01 | $22,407.12 |
DisclosureSEC source: 0001209191-23-041868 · doc4a.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,506,735 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 10:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.07 | $40,701.00 |
DisclosureSEC source: 0001209191-23-040737 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,506,735 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| July 03, 2023 Filed Jul 8, 2023 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 4,414 | $4.07 | $17,965.42 |
DisclosureSEC source: 0001209191-23-041868 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,512,321 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| June 30, 2023 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 4,635 | $3.46 | $16,037.10 |
DisclosureSEC source: 0001209191-24-002738 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,153,300 F1 · kind: Includes 4635 shares of common stock purchased under the Company's Employee Stock Purchase Plan on June 30, 2023 in an exempt transaction. Read SEC document |
| June 01, 2023 Filed Jun 3, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.53 | $45,302.00 |
DisclosureSEC source: 0001209191-23-034100 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,516,735 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 19, 2022. Read SEC document |
| May 26, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 75,000 | $4.50 | $337,335.00 |
DisclosureSEC source: 0001209191-23-032726 · doc4.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,526,735 F3 · kind: Transaction occurred pursuant to a Rule 10B5-1 Plan adopted on December 5, 2022. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 422,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032726 · doc4.xml · derivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 422,000 Underlying: Common Stock, $.01 Par Value · 422,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F4 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F4 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 75,000 | $4.59 | $344,467.50 |
DisclosureSEC source: 0001209191-23-032726 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,601,735 F3 · kind: Transaction occurred pursuant to a Rule 10B5-1 Plan adopted on December 5, 2022. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 345,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032726 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,676,735 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 24, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 150,000 | $4.69 | $702,780.00 |
DisclosureSEC source: 0001209191-23-032032 · doc4.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,331,735 F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 500,000 | $4.79 | $2,395,000.00 |
DisclosureSEC source: 0001209191-23-032032 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,481,735 F2 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 1,000,000 | $4.79 | $4,790,000.00 |
DisclosureSEC source: 0001209191-23-032032 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,981,735 F1 · kind: A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 1,500,000 shares. The acquisition of 500,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. Read SEC document |
| May 18, 2023 Filed May 20, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 16,434 | $4.56 | $74,939.04 |
DisclosureSEC source: 0001209191-23-031286 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,981,735 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2023 Filed May 13, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 21,959 | $4.40 | $96,619.60 |
DisclosureSEC source: 0001209191-23-029235 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,998,169 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 05, 2023 Filed May 6, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.00 | $40,000.00 |
DisclosureSEC source: 0001209191-23-027850 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,020,128 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $4.13 | $41,287.00 |
DisclosureSEC source: 0001209191-23-023542 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,030,128 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 02:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 10,000 | $5.27 | $52,748.00 |
DisclosureSEC source: 0001209191-23-016092 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,040,128 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| August 27, 2022 Filed Aug 30, 2022 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 35,952 | $3.73 | $134,100.96 |
DisclosureSEC source: 0001209191-22-047944 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,048,534 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 10:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 3,147 | $2.93 | $9,220.71 |
DisclosureSEC source: 0001209191-22-043575 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,084,486 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 01:01 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 3,147 | $2.93 | $9,220.71 |
DisclosureSEC source: 0001209191-22-047431 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,084,486 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| May 18, 2022 Filed May 21, 2022 00:01 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 16,434 | $3.19 | $52,424.46 |
DisclosureSEC source: 0001209191-22-031205 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,081,339 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 311,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028680 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,097,773 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 254,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028680 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,786,773 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock,$.01 par value | 27,675 | $2.71 | $74,999.25 |
DisclosureSEC source: 0001209191-22-014094 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,532,773 Read SEC document |
| February 28, 2022 Filed Aug 25, 2022 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock,$.01 par value | 27,675 | $2.71 | $74,999.25 |
DisclosureSEC source: 0001209191-22-047425 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,532,773 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective February 28, 2022. The purchase was approved by the Company's Board of Directors. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 22:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 2,334 | $3.17 | $7,398.78 |
DisclosureSEC source: 0001209191-22-006414 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,505,628 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 10, 2022 02:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 1,804 | $3.17 | $5,718.68 |
DisclosureSEC source: 0001209191-22-008267 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,505,098 F1 · shares: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on January 31, 2022. The amended number of shares purchased were limited by Section 423(b)(8) of the Code. Read SEC document |
| January 31, 2022 Filed Aug 25, 2022 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 1,804 | $3.17 | $5,718.68 |
DisclosureSEC source: 0001209191-22-047422 · doc4a.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,505,098 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
| August 27, 2021 Filed Aug 28, 2021 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 35,358 | $4.91 | $173,607.78 |
DisclosureSEC source: 0001209191-21-053768 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,503,294 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $2.99 | $14,950.00 |
DisclosureSEC source: 0001209191-21-049136 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,538,652 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2021 representing the maximum allowable under the Plan for this period. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 226,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034452 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,533,652 F3 · shares: The restricted stock unit will vest on May 17, 2024 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 17, 2021. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 18, 2021 until May 17, 2024 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 190,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034452 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307,652 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 22:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock,$.01 par value | 3,000 | $3.38 | $10,140.00 |
DisclosureSEC source: 0001209191-21-018600 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,000 Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 23:18 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $1.33 | $6,650.00 |
DisclosureSEC source: 0001209191-21-006887 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,117,560 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective January 31, 2021 representing the maximum allowable under the Plan for this period. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:05 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048844 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,560 F3 · shares: The restricted stock unit will vest on May 22, 2023 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on August 27, 2020. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from August 27, 2020 until May 22, 2023 related to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.